Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase.

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that interfere with the replication of human immunodeficiency virus (HIV) are being pursued with guidance from molecular modeling including free-energy perturbation (FEP) calculations for protein-inhibitor binding affinities. The previously reported pyrimidinylphenylamine 1 and its chloro analogue 2 are potent anti-HIV agents; they inhibit replication of wild-type HIV-1 in infected human T-cells with EC(50) values of 2 and 10 nM, respectively. However, they show no activity against viral strains containing the Tyr181Cys (Y181C) mutation in HIV-RT. Modeling indicates that the problem is likely associated with extensive interaction between the dimethylallyloxy substituent and Tyr181. As an alternative, a phenoxy group is computed to be oriented in a manner diminishing the contact with Tyr181. However, this replacement leads to a roughly 1000-fold loss of activity for 3 (2.5 μM). The present report details the efficient, computationally driven evolution of 3 to novel NNRTIs with sub-10 nM potency toward both wild-type HIV-1 and Y181C-containing variants. The critical contributors were FEP substituent scans for the phenoxy and pyrimidine rings and recognition of potential benefits of addition of a cyanovinyl group to the phenoxy ring.

[1]  William L. Jorgensen,et al.  FEP-guided selection of bicyclic heterocycles in lead optimization for non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006 .

[2]  William L Jorgensen,et al.  Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[3]  Thomas B. Woolf,et al.  Improving the efficiency and reliability of free energy perturbation calculations using overlap sampling methods , 2004, J. Comput. Chem..

[4]  Marie-Pierre de Béthune,et al.  Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). , 2010, Antiviral research.

[5]  Junying Yuan,et al.  Synthetic Study of Substituted Arylsulfonylphenylbenzamides , 2005 .

[6]  R. Martínez,et al.  Synthesis of 5,6-dihydropyrrolo[2,1-a]isoquinolines featuring an intramolecular radical-oxidative cyclization of polysubstituted pyrroles, and evaluation of their cytotoxic activity. , 2010, Organic & biomolecular chemistry.

[7]  H. M. Vinkers,et al.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. , 2004, Journal of medicinal chemistry.

[8]  Omar Haq,et al.  Torsion Angle Preference and Energetics of Small-Molecule Ligands Bound to Proteins , 2007, J. Chem. Inf. Model..

[9]  D. Richman,et al.  Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. , 1988, The Journal of biological chemistry.

[10]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[11]  Julian Tirado-Rives,et al.  Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. , 2002, Journal of medicinal chemistry.

[12]  Julian Tirado-Rives,et al.  Molecular modeling of organic and biomolecular systems using BOSS and MCPRO , 2005, J. Comput. Chem..

[13]  William L. Jorgensen,et al.  Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives. , 2010, Bioorganic & medicinal chemistry letters.

[14]  N. Yamamoto,et al.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. , 1985, Science.

[15]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[16]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[17]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[18]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[19]  R. Gallo,et al.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. , 1984, Science.

[20]  William L Jorgensen,et al.  Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[21]  Christopher D Miller,et al.  Nonnucleoside Reverse Transcriptase Inhibitor Resistance and the Role of the Second-Generation Agents , 2010, The Annals of pharmacotherapy.

[22]  Julian Tirado-Rives,et al.  Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase. , 2006, Bioorganic & medicinal chemistry letters.

[23]  William L. Jorgensen,et al.  Optimization of azoles as anti-human immunodeficiency virus agents guided by free-energy calculations. , 2008, Journal of the American Chemical Society.

[24]  S H Unger,et al.  "Aromatic" substituent constants for structure-activity correlations. , 1973, Journal of medicinal chemistry.

[25]  William L Jorgensen,et al.  Perspective on Free-Energy Perturbation Calculations for Chemical Equilibria. , 2008, Journal of chemical theory and computation.

[26]  S. Buchwald,et al.  Orthogonal Cu- and Pd-based catalyst systems for the O- and N-arylation of aminophenols. , 2009, Journal of the American Chemical Society.

[27]  M. Popovič,et al.  T4 POSITIVE HUMAN NEOPLASTIC CELL LINES SUSCEPTIBLE TO AND PERMISSIVE FOR HTLV-III , 1984, The Lancet.

[28]  Jonathan W. Essex,et al.  Prediction of protein–ligand binding affinity by free energy simulations: assumptions, pitfalls and expectations , 2010, J. Comput. Aided Mol. Des..

[29]  W. L. Jorgensen,et al.  Monte Carlo simulation of differences in free energies of hydration , 1985 .

[30]  D. Richman,et al.  Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Rusconi,et al.  Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1 , 2009 .

[32]  J Tirado-Rives,et al.  Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. , 2001, Bioorganic & medicinal chemistry letters.

[33]  G. Dutschman,et al.  Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro , 1994 .

[34]  C. J. Berg,et al.  CHOLINE PRECURSORS AND ALZHEIMER'S DISEASE , 1982, The Lancet.

[35]  Julian Tirado-Rives,et al.  Potential energy functions for atomic-level simulations of water and organic and biomolecular systems. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Neyts,et al.  Synthesis and anti-CVB 3 evaluation of substituted 5-nitro-2-phenoxybenzonitriles. , 2008, Bioorganic & medicinal chemistry letters.

[37]  D. Hazuda,et al.  The Challenge of Finding a Cure for HIV Infection , 2009, Science.

[38]  K. Anderson,et al.  Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent , 2002, Antimicrobial Agents and Chemotherapy.

[39]  Martin Stahl,et al.  Small Molecule Conformational Preferences Derived from Crystal Structure Data. A Medicinal Chemistry Focused Analysis , 2008, J. Chem. Inf. Model..

[40]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[41]  R. Giridhar,et al.  The search for potent, small molecule NNRTIs: A review. , 2009, Bioorganic & medicinal chemistry.

[42]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.